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Summary High dose chemotherapy with autologous bone marrow transplantation (ABMT) has shown
promise in several types of cancer. There is, however, a risk of transfusing contaminating tumour cells with the
bone marrow cells, e.g. in patients with small cell lung carcinoma (SCLC). To eliminate SCLC cells from
normal human bone marrow, four monoclonal antibodies reactive with SCLC cells were used with
immunomagnetic beads in model experiments. With two cycles of immunomagnetic elimination the individual
antibodies removed 2.5-4.4 log of H-146 tumour cells from a single cell suspension, as assessed in a highly
reproducible soft agar assay. Different combinations of two antibodies were only marginally more effective
than the individual MAbs, whereas 5-6 log removal was obtained with a combination of all four antibodies.
The method was equally effective when the tumour cells were mixed with bone marrow cells at a ratio of 1:10.
The immunomagnetic procedure did not significantly affect the survival of normal progenitor cells, assessed in
CFU-GM and CFU-GEMM assays. The results indicate that the procedure safely and effectively can be used
to eliminate tumour cells from the bone marrow in conjunction with ABMT in patients with SCLC.
Most patients with small cell lung cancer (SCLC) have
disseminated disease at time of diagnosis. Although SCLC is
initially very sensitive to chemotherapy, the responses are of
short duration and relapse of the disease occurs rapidly in
90-95% of the cases. For limited disease the 5-year survival
rate is only about 5-10% (Albain et al., 1991), and the
2-year survival rate for extensive disease is less than 6%
(Albain et al., 1991).
To improve the situation, autologous bone marrow trans-
plantation (ABMT) combined with high dose chemotherapy
has been tried (Humblet et al., 1987; Symann et al., 1989;
Souhami et al., 1989; Williams et al., 1989; Marangolo et al.,
1989; Nomura et al., 1990; Lazarus et al., 1990; Gomm et al.,
1991). This treatment has increased the number of patients
with complete remissions (Humblet et al., 1987; Souhami et
al., 1989) and improved relapse free-survival (Humblet et al.,
1987; Symann et al., 1989), but, unfortunately, the long time
survival rate has not increased significantly. One contributing
factor may be infiltration of tumour cells in the transfused
bone marrow. It has become increasingly clear that tumour
cells are often present in the marrow of SCLC patients, even
if cytomorphological and histomorphological analysis re-
mains negative (Stahel et al., 1985; Berendsen et al., 1988;
Canon et al., 1988; Trillet et al., 1989; Beiske et al., 1992). In
order to prevent giving tumour cells back to the patient, it is
logical to purge the bone marrow for tumour cells before
reinfusion. The usefulness of immunological, physical and
chemical procedures have been examined for this purpose
(Gordon et al., 1984; Mabry et al., 1985; Okabe et al., 1985;
Benard et al., 1988; Combaret et al., 1988; Vredenburgh &
Ball, 1990; Humblet et al., 1989; Meagher et al., 1989; Elias
et al., 1990).
In this study the purging efficacy of immunomagnetic
beads used in combination with four different monoclonal
antibodies (MAbs), previously selected from a panel of
17 MAbs (Myklebust et al., 1991), was tested in preclinical
model experiments. The optimal procedure involved the use
of a mixture of all four MAbs and two purging cycles,
resulting in as high as 6 log of tumour cell depletion with an
acceptable recovery of normal bone marrow progenitor cells.
Materials and methods
Bone marrow
Human bone marrow aspirates were obtained from healthy
volunteers or from patients at the Norwegian Radium Hos-
pital with non-SCLC malignancies that were free of tumour
cells in their marrow. All samples were obtained with in-
formed consent from the donors. Ten ml of bone marrow
were layered upon Lymphoprep (Nycomed, Oslo, Norway)
and the mononuclear cell fraction was obtained by cen-
trifugation at 1200 r.p.m. for 30 min. The mononuclear cells
were washed once in phosphate buffered saline (PBS) before
being used in the experiments.
Cell line
The H-146 human SCLC cell line (Carney et al., 1985),
kindly provided by Dr Adi F. Gazdar, National Cancer
Institute, Bethesda, MD, USA, was used in the experiments.
The cells were grown as suspension cultures in RPMI 1640
medium (Gibco, Paisley, UK) supplemented with 10% foetal
calf serum (FCS).
Monoclonal antibodies
MOC-1 (Leij et al., 1985) and MOC-31 (Leij et al., 1986)
antibodies were gifts from Dr L. de Leij, Groningen, The
Netherlands. MOC-1 (IgGI) binds to the neural cell adhesion
molecule (CD56/NCAM) (Moolenaar et al., 1990), and
MOC-31 (IgG2a) to an epithelial antigen (cluster 2). NrLulO
(also denoted TFS-2), an IgG2b antibody recognising a
39 kDa antigen (Okabe et al., 1984), was obtained from
NeoRx Corporation, Seattle, WA, USA. MLuCl (earlier
denoted MOvl5), kindly provided by Dr Sylvie Menard,
Milan, Italy, is an IgGI antibody that binds to a saccharide
epitope carried by neutral glycolipids, glycoproteins and
mucins (Ripamonti et al., 1987).
Immunomagnetic beads
The immunomagnetic beads used, DynabeadsR M-450 SAM
IgG ST (Dynal, Oslo, Norway), are uniform, magnetic,
polystyrene beads with sheep anti mouse IgG (SAM)
antibodies covalently bound to their surface. SAM bind all
mouse IgG subclasses.
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Immunomagnetic separationprocedure
Mechanically dispersed tumour cells (1 x 107), mononuclear
bone marrow cells (2 x 106), or mixes of both (total 5 x 107)
were incubated in plastic tubes for 30min at 4°C with one or
more MAbs (10 g of each) in 1 ml of RPMI 1640, supp-
lemented with 10% FCS, 100 units ofpenicillin and 100pl of
streptomycin (Gibco) per ml medium. The cells were washed
twice in PBS with 1% FCS before adding the immuno-
magnetic beads suspended in 0.5 ml of medium and then
incubated at 4°C for 30 min. In the experiments with the cell
line the ratio of beads to tumour cells was 50:1, and in the
control experiments to test the effect on bone marrow pro-
genitor cells the ratio of beads to nucleated bone marrow
cells was also 50:1. To ensure proper contact between cells
and MAbs/beads, during the incubations, the tubes were
rolled on a mixer (Coulter Electronics Ltd., UK). Tumour
cells were removed from the suspension by placing a flat
cobalt samarium magnet to the wall of the tubes. After 1 min
the suspension with remaining cells was aspirated, centri-
fugated at 1000 r.p.m. for 5 min, and the cells resuspended in
1 ml of medium. Remaining clonogenic tumour cells and
bone marrow cells in the suspension were measured by
colony-forming assays as described below. In some experi-
ments, a repeat cycle of immunomagnetic separation was
performed.
Colony-forming assaysfor tumour andbone marrow progenitor
cells
The number ofcolony forming tumour cells was assessed in a
soft agar assay (Courtenay & Mills, 1978), as previously
described for malignant B cells (Kvalheim et al., 1987).
Briefly, soft agar cultures were set up in triplicates in 10 ml
tubes by adding 0.2 ml August rat blood diluted 1 to 8,
0.2 ml of appropriately diluted bone marrow/tumour cell
suspensions, and 0.6 ml of 0.5% agar (Difco Laboratories,
Detroit, Michigan, USA). The tubes were incubated at 37°C
in 5% 02, 5% CO2, and 90% N2, and after 21 days of
incubation colonies of more than 50 cells were counted using
a Zeiss stereo microscope.
The clonogenic progenitor cells remaining in the bone
marrow after immunobead separation were assessed in a
modified version (Kvalheim et al., 1987) of the method des-
cribed by Burgess et al. (1977). Mononuclear BM cells were
suspended at a concentration of 2 x I05 cells ml-' in
MCCOY'S 5A medium (Gibco) containing 0.3% agar, 15%
FCS, 20 ng of GM-CSF (kindly provided by Schering
Plough, NJ, USA) and antibiotics. Triplicate 1 ml aliquots
were cultured in 35 mm plastic dishes at 37'C in 5% 02, 5%
CO2, and 90% N2. After 14 days of incubation colonies of
more than 40 cells were counted.
In the GEMM assay (Messner et al., 1982), 2 x 105
mononuclear cells were suspended in 1 ml Iscove's modified
Dulbecco's medium (Gibco) containing 0.8% methylcellulose,
10% FCS, 10% leucocyte conditioned medium, 30% human
plasma, 5 x 10-5 M 2-mercaptoethanol and 1 unit of erythro-
poietin (Cilag Ltd., Schaffhausen, Switzerland). Triplicate
1 ml aliquots were cultured and colonies counted as for the
GM assay.
Results
Cloning efficiency ofSCLC cells
When different numbers of H-146 cells were seeded out in
soft agar the number of colonies formed was proportional to
the number of cells plated (Figure 1). This relationship was
close to linear down to ten cells plated per tube, and the
plating efficiency calculated from the slope of the curve was
approximately 40% in three independent experiments.
Similar curves were established in each model experiment,
and the curves were used to calculate the tumour cell deple-
tion obtained by the treatment, taking the plating efficiency
in each experiment into account. Efficacy of the treatment is
given as the logarithm of the number of tumour cells
removed.
Tumour cell removal
Efficacy of immunobeads used with single and combinations of
two MAbs Of the individual MAbs, MOC-1 and NrLulO
were the most effective in the immunomagnetic procedure,
resulting in 3.7 log and 3.6 log tumour cell removal, respec-
tively (Table I). The corresponding value for MLuCl was
2.6 log, compared to 2.1 log for MOC-31. When the proce-
dure was performed twice, a significant increase in efficacy
was obtained for MOC-1 (4.4 log depletion) and for MLuCl
(4.2 log depletion), whereas the values with the other two
MAbs increased only slightly (Table I).
Since it is known that tumour-associated antigens com-
monly are heterogeneously expressed on tumour cells, we
wanted to test different combinations of two MAbs. As can
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Figure 1 Sensitivity and reproducibility of the soft-agar assay of
clonogenic tumour cells. Different cell numbers of the human
small cell lung cancer line H-146 were seeded out in the assay as
described in Materials and methods. Each point represents the
mean of results obtained in three independent experiments, each
in triplicate. Bars indicate s.d.
Table I Efficacy ofsheep anti-mouse (SAM)-coated paramagnetic particles (immunobeads) in removing H-146 small cell lung cancer cells
incubated with different primary antibodies, individually and in combinations of two
Log tumour cell depletiona (mean)b
Individual MAbs Combination oftwo MAbs
One cycle of Two cycles One cycle ofelimination Two cycles ofelimination
Mab elimination ofelimination MOC-J MOC-31 NrLulO MLuCJ MOC-1 MOC-31 NrLuJO MLuCJ
MOC-1 3.7 4.4 - 3.0 3.9 3.6 - 4.1 4.1 4.2
MOC-31 2.1 2.5 3.0 - 3.7 3.8 4.1 - 4.6 4.7
NrLulO 3.6 3.9 3.9 3.7 - 4.0 4.1 4.6 - 4.2
MLuCl 2.6 4.2 3.6 3.8 4.0 - 4.2 4.7 4.2 -
H-146 cells were incubated for 30 min at 4°C with MAbs(10figml-' ofeach) and then for 30 min with SAM-M-450 Dynabeads at a ratio
beads to tumourcells of50: 1. aCalculated from the number ofcolonies counted, taking theplatingefficiency into account, and determined as
the logarithm ofthe number ofcells depleted by the treatment. bMean ofthe results obtained in2-3 independent soft agar experiments, each
performed in triplicate.
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be seen from Table I, the different combinations gave log
tumour cell depletions in the range of 3.0-4.7. In most cases
the combinations were not more effective than the most
effective single antibody, except in some experiments involv-
ing MOC-31 and MLuC1. The results were clearly improved
by performing the elimination procedure twice. The overall
best results were obtained with combinations of either MOC-
31 and MLuCl or NrLulO and MOC-31, resulting in
4.6-4.7 log tumour cell depletion.
Combinations of three and four MAbs In the next set of
experiments, combinations of three (MOC-1 + MOC-
31 + NrLulO) and four (MOC-1 + MOC-31 + NrLulO +
MLuC1) antibodies were tested. As can be seen from the
results presented in Table II, neither of the combinations was
more effective than the most active single antibodies (Table I)
when only one cycle of immunomagnetic removal was used.
With two cycles, however, the tumour cell depletion with a
combination of three MAbs increased to 4.7 log, a com-
parable efficacy to that of the most effective 2-MAb com-
bination. This value was further increased to 5.1 log when an
additional incubation with the antibodies was introduced
before the second cycle of immunomagnetic separation
(Table II). The most effective treatment was obtained with
two elimination cycles involving the combination of four
antibodies. Thus, the mean log tumour cell depletion
obtained in three different experiments was 5.6 log, ranging
from 5.3 to at least 6 logs. In this case, the additional incuba-
tion with the MAbs did not improve the results.
With the encouraging results obtained, the combinations of
three and four MAbs were also tested in the more clinically
relevant situation with H-146 tumour cells added to fresh
human bone marrow at a ratio of 1:10. In repeat
experiments, a mean log tumour cell depletion of 4.8 was
obtained with a mixture of three MAbs (Table III). In one of
the experiments, only 10 out of 1 x 106 tumour cells plated
remained in the bone marrow after purging, as calculated
from the number of colonies formed in soft agar. Even more
encouraging, with the combination of four MAbs no colony
formation in soft agar was observed with a tumour cell/bone
marrow mixture that contained 1 x 106 SCLC cells before
purging. Since the same result was obtained in three indepen-
dent experiments, it can be concluded that with the 4 MAb
combination at least 6 log tumour cell depletion from the
bone marrow can be achieved, a result that is even better
than when the procedure was performed without the presence
of bone marrow cells.
Survival ofprogenitor bone marrow cells
The effect of the immunomagnetic procedure on the survival
of normal bone marrow progenitor cells was assessed (Table
IV). With single antibodies, the fraction of surviving CFU-
GM differed with the antibodies from 80 to 49%, the lowest
value was seen in experiments with MLuCl. With three and
four MAb combinations, the fraction of surviving CFU-GM
was 68% and 52%, respectively. The combinations were also
tested in the CFU-GEMM assay, where it was found that
70-80% of the progenitor cells had survived the
immunomagnetic treatment. The results indicate that the
immunomagnetic purging procedure involving combinations
of MAbs can be used safely for purging purposes in patients.
Discussion
A magnetic procedure was developed for removing SCLC
cells from human bone marrow. We have demonstrated that
by using a combination of four antibodies and immuno-
magnetic sheep anti-mouse IgG beads, a 6-log tumour cell
separation could be achieved, as determined by a reproduc-
ible clonogenic soft agar assay. The procedure reduced the
survival of normal bone marrow progenitor cells to only a
limited extent, showing that the procedure can be safely used
in a clinical setting.
Heterogeneity of tumour cell surface antigen expression
suggests that a cocktail of MAbs may be necessary to achieve
effective removal of tumour cells. This was confirmed in the
present work, as the best results were obtained with a com-
bination of all four MAbs. The MAbs were selected because
of their ability to bind to small cell lung cancer cells, and not
to normal cells in bone marrow and peripheral blood
(Myklebust et al., 1991). Also, the usefulness of the same
antibodies for detecting bone marrow metastases in small cell
lung cancer patients has recently been demonstrated (Beiske
et al., 1992). We have found that the NrLulO and MOC-31
antibodies bind to the same antigen, but to different epitopes
(unpublished data). However, they differ in their ability to
Table II Efficacy of immunobeads in eliminating H-146 cells incubated with combinations of three or four
anti-small cell lung cancer antibodies. Effect of repeat immunomagnetic removal with and without additional
incubation with primary antibodies
Log tumour cell
Number of Cycle of depletion
MAbs experiments Elimination MAbs (mean) (range)
MOC-1 + MOC-31 + NrLulO 3 1 1 3.8 3.4- 4.1
3 2 1 4.7 4.4- 5.1
2 2 2 5.1 5.0- 5.2 MOC-l + MOC-31 + NrLuIO + MLuC1 2 1 1 3.3 2.7- 3.8
3 2 1 5.6 5.3->6.0
1 2 2 5.4
Treatment and calculations as in Table I.
Table III Removal ofH-146 cells from fresh human bone marrow using immunobeads and a mixture ofthree or
four monoclonal antibodies
Tumour cells Log tumour cell
Number of Tumour cells remaining depletion
MAbs experiments plated (mean) (mean) (range)
MOC-1 + MOC-31 + NrLulO 2 105 3 4.8 4.5-5.0
106 10
MOC-l + MOC-31 + NrLul0 + MLuCl 3 106 0 >6.0 >6.0
H-146 cells mixed with bone marrow cells (ratio 1:10) were incubated with the MAbs (10jg ml-' ofeach) and
then with SAM-M-450 Dynabeads at a ratio tumour cells to beads of 1:50. Two purging cycles were used.
Calculations as in Table I.1334 A.T. MYKLEBUST et al.
Table IV Survival ofnormal bone marrow progenitor cells after treatmenta with monoclonal antibodies and
immunobeads
CFU-GM CFU-GEMM
No. of Fraction No. of Fraction
colonies ofcontror colonies ofcontrot
MAbs (mean)b (%) (range) (mean)" (%) (range)
None 111 80 69-100 nt
MOC-1 106 67 53- 75 nt
MOC-31 97 86 70- 99 nt
NrLulO 90 67 59- 75 nt
MLuCl 69 49 32- 69 nt
MOC-1 + MOC-31 + NrLulO 96 68 61- 83 137 70 67-74
MOC-1 + MOC-31 + NrLulO + MLuCl 70 49 45- 56 135 80 64-94
aTwo x 105 nucleated bone marrow cells were incubated with the MAbs(10jig ml
-l ofeach), and then with
immunobeads ataratio beads tomononuclearcellsof50:1, in bothcasesfor 30 minat4°C. bMeanoftheresults
in three independent experiments, each in triplicate. cFraction ofremaining colonies calculated relative to the
number of colonies in untreated control cultures.
detect contaminating SCLC cells in fresh bone marrow
aspirates (Beiske et al., 1992), and as suggested by the pres-
ent results, both antibodies should be included in a cocktail
recommended for clinical use, together with MOC-1 and
MLuCl that recognise distinct antigens (Moolenaar et al.,
1990; Ripamonti et al., 1987).
To limit the need for fresh human bone marrow, the
removal experiments with individual and combinations of
two MAbs were performed on a suspension of H-146 cells
only, as previous experience has shown that such experiments
closely predict results obtained when tumour cells are mixed
with normal bone marrow cells. In accordance with this, the
present procedure proved to be equally effective when H-146
tumour cells were mixed with bone marrow cells at a ratio of
1:10. Thus, the optimal combinations of four MAbs resulted
in a mean log tumour cell removal of 5.6 in the absence, and
>6.0 in the presence of bone marrow cells. In experiments
with MOC-31 antibody no difference in log tumour cell
removal was found between 1:10 and 1:100 mixes of SCLC
and marrow cells (not shown). However, limited access to
human bone marrow and the high efficacy of the purging
method prevented further testing at a low tumour to bone
marrow cell ratio. The validity of calculating log tumour cell
removal is dependent on a close to linear relationship
between the number of tumour cells plated and the number
of soft agar colonies formed. This requirement was met with
the H-146 cell line, which showed a high and reproducible
plating efficiency in the clonogenic assay.
Several reports have described methods to eliminate SCLC
cells from bone marrow (Gordon et al., 1984; Mabry et al.,
1985; Okabe et al., 1985; Benard et al., 1988; Vredenburgh &
Ball, 1990; Humblet et al., 1989; Meagher et al., 1989; Elias
et al., 1990). Vredenburgh & Ball (1990) obtained 4-5 log
separation using immunomagnetic beads and three different
antibodies, administered at a relatively high concentration,
whereas the results of Elias et al. (1990) were less satisfactory
(2.4-2.6 log). In both cases, two types of immunobeads had
to be used because their tumour-associated primary
antibodies were of both IgG and IgM isotypes. The results
reported for other depletion procedures show varying degrees
ofefficacy and toxicity to normal bone marrow cells (Gordon
et al., 1984; Mabry et al., 1985; Okabe et al., 1985; Benard et
al., 1988; Meagher et al., 1989), the best results (4-5 log
depletion) obtained by Humblet et al. (1989). The latter
investigators combined immunological and pharmacological
methods, and their regime was relatively toxic to bone mar-
row progenitor cells.
Altogether, the results in the present work were better than
any of those previously reported, probably reflecting both the
efficacy of immunomagnetic procedures (Kiesel et al., 1987;
Kvalheim et al., 1988) and the properties of the antibodies
used. In agreement with the experience of Vredenburgh &
Ball (1990), the best results were obtained with two purging
cycles at a 50:1 ratio of beads to tumour cells. The procedure
had only minor effects on cell survival in the bone marrow
progenitor cell assays. Some bone marrow specimens used for
these studies were obtained from patients with other types of
malignancies but without bone marrow involvement. In a few
of these cases, the proliferative capacity of the progenitor
cells was relatively low. This did not influence the results,
except that with MLuCl used alone an unpredictable varia-
tion in the number of surviving CFU-GMs was observed in
some experiments.
High dose chemotherapy followed by ABMT in SCLC
patients has been used by several investigators (Humblet et
al., 1987; Symann et al., 1989; Souhami et al., 1989; Williams
et al., 1989; Marangolo et al., 1989; Nomura et al., 1990;
Lazarus et al., 1990; Gomm et al., 1991), but no improve-
ment in survival, compared to patients treated with standard
chemotherapy, has been reported. Several factors may have
contributed to the reported limited benefit of ABMT, includ-
ing a less than optimal patient selection with regards to stage
of the disease, age, response to induction therapy, and timing
and intensity of the ablative treatment. Moreover, with the
development of sensitive diagnostic techniques it has become
increasingly clear that a high number of SCLC patients have
contaminating tumour cells in their bone marrow (Stahel et
al., 1985; Berendsen et al., 1988; Canon et al., 1988; Trillet et
al., 1989; Beiske et al., 1992). It should also be noted that the
detection of tumour cells in bone marrow is based on studies
of small volume aspirates, whereas about 11 of bone marrow
is harvested for ABMT. Thus, the risk of tumour cell con-
tamination of the transfused marrow may be higher than
indicated by studying bone marrow aspirates.
One argument against ABMT in SCLC has been that
several patients have relapsed locally in the lungs. It cannot
be excluded, however, that these relapses are associated with
i.v. transfusion of contaminated bone marrow cells. The
reinfused cells will meet the first capillary bed in the lungs,
and it is well known that interaction between tumour cells
and host tissues favours tumour growth in orthotopic sites,
in this case represented by the lungs. Furthermore, the effect
of tumour cell trapping in the lungs is also exemplified by the
finding of Glorieux et al. (1986) that a patient with neuro-
blastoma and another with Burkitts lymphoma developed
diffuse carcinomatosis in the lungs after ABMT.
In cancer types where patients undergoing ABMT are at
risk for having contaminating tumour cells in the bone mar-
row, it seems logical that the marrow should be purged
before transfusion. Although the value of tumour cell purg-
ing has not been definitely proven, recent evidence indicates
that effective removal of lymphoma cells from the marrow
has a significant effect on the clinical outcome (Gribben et
al., 1991). We have previously developed highly effective
immunomagnetic methods which are currently in routine
clinical use in patients with B and T-cell malignancies
(Kvalheim et al., 1988; Wang et al., 1992). The similar
method described here for purging SCLC has been shown to
be equally efficacious in tumour cell depletion from bone
marrow, and the method is recommended for use in conjunc-
tion with ABMT in selected groups of SCLC patients.IMMUNOMAGNETIC BONE MARROW PURGING OF SCLC CELLS 1335
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